Thermo Fisher Scientific launches next-generation microarray solution

Thermo Fisher Scientific has introduced the Applied Biosystems™ SwiftArrayStudio™ Microarray Analyzer, designed for fast and scalable sample analysis. In conjunction with two new arrays – the Applied Biosystems Axiom™ PharmacoPro™ Array and the Applied Biosystems Axiom PangenomePro Array – the analyzer combines four key genotyping processes into a single, integrated device.

This enables researchers to cover the widest range of populations for Genome-Wide Association Studies (GWAS) and accelerate breakthrough discoveries in pharmacogenomics that will help drive the future of precision medicine forward.

As genetic science advances, researchers need faster, simpler ways to analyze samples. Traditional workflows can take days to complete and require extensive hands-on time. Large labs also face wide variability in customer needs, often demanding multiple instruments and specialized expertise to deliver results.

The SwiftArrayStudio Microarray Analyzer enables labs to be agile, seamlessly scaling throughput and optimizing performance as demand changes, without sacrificing data quality. The all-in-one platform delivers results in as little as 30 hours through a modern, easy-to-use design that reduces hands-on time by up to 40% (according to internal data on file). This efficiency lowers costs and complexity, helping researchers generate high quality data faster and with less effort.

The new SwiftArrayStudio analyzer redefines what microarray technology can offer. Its enhanced features and flexibility enable scientists to unlock new research initiatives, such as population-scale genotyping and pharmacogenomics, with hope in the future to bring treatments to individuals faster.

“The SwiftArrayStudio analyzer represents more than just technical advancement – it’s an advancement for genomics research, powering a new generation of innovation for our customers,” said Ravi Gupta, vice president and general manager of Thermo Fisher Scientific’s microarray business.

“Designed as a single, expandable platform to meet future technological needs around genotyping, methylation, epigenetics, reproductive health, agrigenomics and many other applications, the platform delivers robust capabilities through an uncompromised user experience,” he added.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>